Sign In
Buy AMGN
$338.22
+9.96 (+3.03%)
At Close: Jun 03, 2026
Procter & Gamble (NYSE:PG) Stock Acquired Rep. David Taylor
03:06am, Friday, 23'rd Jan 2026
Representative David Taylor (R-Ohio) recently bought shares of Procter and Gamble Company (The) (NYSE: PG). In a filing disclosed on January 21st, the Representative disclosed that they had bought bet
Rep. David Taylor Buys Microsoft Corporation (NASDAQ:MSFT) Stock
03:06am, Friday, 23'rd Jan 2026
Representative David Taylor (R-Ohio) recently bought shares of Microsoft Corporation (NASDAQ: MSFT). In a filing disclosed on January 21st, the Representative disclosed that they had bought between $1
Rep. David Taylor Sells Lam Research Corporation (NASDAQ:LRCX) Stock
02:34am, Friday, 23'rd Jan 2026
Representative David Taylor (R-Ohio) recently sold shares of Lam Research Corporation (NASDAQ: LRCX). In a filing disclosed on January 21st, the Representative disclosed that they had sold between $15
Rep. David Taylor Purchases Shares of International Business Machines Corporation (NYSE:IBM)
02:34am, Friday, 23'rd Jan 2026
Representative David Taylor (R-Ohio) recently bought shares of International Business Machines Corporation (NYSE: IBM). In a filing disclosed on January 21st, the Representative disclosed that they ha
International Business Machines (NYSE:IBM) Shares Acquired Rep. David Taylor
02:34am, Friday, 23'rd Jan 2026
Representative David Taylor (R-Ohio) recently bought shares of International Business Machines Corporation (NYSE: IBM). In a filing disclosed on January 21st, the Representative disclosed that they ha
Amgen: A Buy In 2026 On Exciting MariTide Obesity - T2D Potential
11:15am, Thursday, 22'nd Jan 2026
Amgen Inc. is rated a Buy, driven by robust pipeline prospects and the transformative potential of its obesity drug candidate MariTide. Recent AMGN performance includes 12% revenue growth in Q3 2025,
Dynasty Wealth Management LLC Takes $445,000 Position in Amgen Inc. $AMGN
04:43am, Wednesday, 21'st Jan 2026
Dynasty Wealth Management LLC acquired a new stake in shares of Amgen Inc. (NASDAQ: AMGN) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The
Americana Partners LLC Lowers Stock Holdings in Amgen Inc. $AMGN
03:26am, Wednesday, 21'st Jan 2026
Americana Partners LLC reduced its position in Amgen Inc. (NASDAQ: AMGN) by 12.0% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Comm
Nonprofit Health Services Organization Files Lawsuit Against Fortune 500 Pharmaceutical Company Over Prescription Drug Access
11:34am, Tuesday, 20'th Jan 2026
LAS VEGAS--(BUSINESS WIRE)--Sagebrush Health Services, a nonprofit organization serving over 10,000 Nevada patients, has filed a lawsuit against Amgen Inc. (NASDAQ: AMGN), alleging that Amgen acted un
Essex LLC Sells 61 Shares of Amgen Inc (AMGN)
09:16am, Tuesday, 20'th Jan 2026
Summary Essex LLC reduced its stake in Amgen Inc (AMGN) by 5.09%, selling 61 shares and holding 1,138 shares valued at about $372,640 as of the latest
2 Dividend Stocks to Buy and Hold For 10 Years
01:58pm, Monday, 19'th Jan 2026
These drugmakers can perform well despite competition and patent cliffs facing them. Both have excellent dividend programs and have increased their payouts at a good clip.
Courier Capital LLC Lowers Stake in Amgen Inc. $AMGN
05:02am, Monday, 19'th Jan 2026
Courier Capital LLC lessened its stake in shares of Amgen Inc. (NASDAQ: AMGN) by 15.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. Th
Amgen's Weight-Loss Drug Shows Promise With Less Frequent Dosing
04:40pm, Thursday, 15'th Jan 2026
Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator from Eli Lilly and Novo Nordisk.
Amgen (AMGN) Advances While Market Declines: Some Information for Investors
06:51pm, Wednesday, 14'th Jan 2026
In the latest trading session, Amgen (AMGN) closed at $328.97, marking a +1.44% move from the previous day.
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses
12:36pm, Wednesday, 14'th Jan 2026
At a J.P. Morgan Healthcare Conference on Monday, Amgen Inc. (NASDAQ: AMGN) CEO Robert Bradway shared findings from part 2 of the Phase 2 Study of MariTide, its investigational obesity treatment.
